You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

TRANXENE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Tranxene patents expire, and when can generic versions of Tranxene launch?

Tranxene is a drug marketed by Ajenat Pharms and is included in one NDA.

The generic ingredient in TRANXENE is clorazepate dipotassium. There are eight drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the clorazepate dipotassium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Tranxene

A generic version of TRANXENE was approved as clorazepate dipotassium by AUROBINDO PHARMA on July 17th, 1987.

  Sign Up

Summary for TRANXENE
Drug patent expirations by year for TRANXENE
Drug Prices for TRANXENE

See drug prices for TRANXENE

Recent Clinical Trials for TRANXENE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Assistance Publique - Hôpitaux de ParisPhase 3
Polish Lymphoma Research GroupPhase 4
Ranbaxy Laboratories LimitedN/A

See all TRANXENE clinical trials

US Patents and Regulatory Information for TRANXENE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ajenat Pharms TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-001 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ajenat Pharms TRANXENE SD clorazepate dipotassium TABLET;ORAL 017105-005 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ajenat Pharms TRANXENE clorazepate dipotassium TABLET;ORAL 017105-006 Approved Prior to Jan 1, 1982 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRANXENE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ajenat Pharms TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-003 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Ajenat Pharms TRANXENE clorazepate dipotassium CAPSULE;ORAL 017105-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Ajenat Pharms TRANXENE clorazepate dipotassium TABLET;ORAL 017105-008 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for TRANXENE

See the table below for patents covering TRANXENE around the world.

Country Patent Number Title Estimated Expiration
Canada 958707 ORTHO-AMINO ARYL KETIMINES, HETEROCYCLIC DERIVATIVES THEREOF AND PREPARATION THEREOF ⤷  Sign Up
Guatemala 197745697 PROCEDIMIENTO PARA PREPARAR ORTOAMINO-ARIL-CETIMINAS ⤷  Sign Up
Netherlands 155545 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.